Nexsphere-F Knee OA Data: Solid Safety, Undifferentiated Efficacy, Payer Case Unbuilt

NextBiomedical's Nexsphere-F Cuts Knee Osteoarthritis Pain by 57%

NextBiomedical's Nexsphere-F, an artery-blocking device, demonstrated significant efficacy in a European prospective observational study for knee osteoarthritis. The gelatin-based, fast-resorbable microspheres led to a mean 57% reduction in pain among 194 patients who were non-responders to conventional treatments. The study, published in Radiology, also reported statistically significant improvements in key knee injury and osteoarthritis outcomes, with approximately 80% of patients achieving the minimum clinically important difference. Crucially, the device showed a favorable safety profile with no moderate-to-severe treatment-related adverse events and only transient skin discoloration in 6.3% of procedures. With a CE Medical Device Directive mark in Europe, NextBiomedical aims to establish Nexsphere-F as a standard of care. The company is also pursuing US market entry through the ongoing RESORB clinical trial (NCT06872567), which plans to enroll around 126 patients.

• The European prospective observational study, involving 194 patients unresponsive to corticosteroids or hyaluronic acid, revealed a mean 57% reduction in knee osteoarthritis pain following treatment with Nexsphere-F. Beyond pain relief, patients experienced statistically significant improvements in key measures of knee injury and osteoarthritis outcomes. Notably, around 80% of participants achieved the minimum clinically important difference, underscoring the device's substantial clinical benefit in a challenging patient population.
• Nexsphere-F demonstrated an excellent safety profile, with no moderate-to-severe treatment-related adverse events reported across over 239 procedures. A key differentiator is its fast-resorbable gelatin-based microspheres, which resulted in only transient skin discoloration in 6.3% of cases, resolving within 24 hours. This contrasts favorably with permanent microsphere approaches, such as Varian’s Embozene, which have been linked to higher rates (up to 65%) of persistent skin discoloration, highlighting Nexsphere-F's improved tolerability.
• NextBiomedical is strategically positioning Nexsphere-F to become a standard of care in genicular artery embolisation, leveraging its current CE Medical Device Directive mark in Europe. To expand its market presence, the company is actively pursuing entry into the US market through the ongoing RESORB clinical trial (NCT06872567). This trial, designed to enroll approximately 126 patients, is a critical step towards securing regulatory approval and establishing the device's role in clinical practice across different geographies.

Addressing the Limitations in Current Knee Osteoarthritis Care

Current knee osteoarthritis (KOA) care remains suboptimal across multiple dimensions, with persistent gaps in evidence quality, clinical trial design, equitable treatment allocation, and real-world accessibility. These limitations collectively hinder the development of standardized, effective, and inclusive management strategies for a condition that increasingly burdens an ageing global population.

• Sex and gender disparities in care: Women present for KOA treatment at more advanced disease stages with more debilitating pain than male counterparts, yet healthcare providers are more likely to recommend total joint arthroplasty for male patients. Differences in knee anatomy, kinematics, prior injury history, and hormonal influences may contribute to these disparities, underscoring the need for inclusive treatment frameworks.

• Surgical evidence gaps: No study has directly compared osteotomy versus conservative treatment for unicompartmental KOA, and no evidence demonstrates whether osteotomy is more effective than unicompartmental knee replacement or non-operative management. Conclusions supporting valgus high tibial osteotomy are based on within-group comparisons rather than non-operative controls, significantly limiting their interpretive value.

• Methodological weaknesses in osteotomy research: Follow-up durations in studies comparing osteotomy techniques were insufficient to capture treatment failure leading to revision arthroplasty. Evidence quality for most comparative osteotomy outcomes was downgraded to low due to limited study numbers, small participant cohorts, and design-level limitations; selective outcome reporting was further obscured by the absence of published study protocols in 11 studies.

• Clinical trial design constraints: Early-stage KOA treatment approaches remain under active debate, and the low 4-year cumulative incidence of total knee replacement (4.3%) creates substantial sample size requirements — ranging from 229 to 3,028 participants per arm depending on endpoint — rendering TKR alone impractical as a standalone DMOAD trial endpoint given feasibility constraints.

• Accessibility and consistency barriers in non-surgical interventions: Gait modification interventions have produced variable outcomes and have historically depended on in-person biofeedback, limiting scalability. For imaging-based monitoring, standardization of acquisition and analysis methods — particularly for weight-bearing CT assessments — will be required to enable reliable longitudinal evaluation, and the literature investigating factors affecting the ability to track bone and joint parameter changes over time remains sparse.

Nexsphere-F Demonstrates Significant Pain Reduction in European Study

Recent clinical investigations into knee osteoarthritis (KOA) have evaluated a diverse range of interventions across pharmacological, biological, and surgical categories. A 2026 systematic review and meta-analysis of 28 RCTs examining intra-articular mesenchymal stem cell (MSC)-based therapies demonstrated significant improvements in pain outcomes — including post-treatment VAS (MD −3.55; p = 0.01) and KOOS pain (MD 15.37; p = 0.03) — along with functional gains in KOOS ADL (MD 12.84; p = 0.04) and KOOS sports (MD 11.76; p < 0.001). However, MRI-based WORMS scores showed no significant change, positioning MSC therapies as symptom-modifying rather than structure-modifying interventions. Safety signals included elevated rates of injection-site pain (RR 2.04; p = 0.0005) and joint swelling (RR 3.39; p = 0.0003), though serious complications such as infection were uncommon. A separate 2026 meta-analysis of seven studies (n = 1,237) assessed oral metformin in overweight and obese adults (BMI ≥25 kg/m²) with symptomatic KOA, reporting a significant reduction in knee pain (SMD: −0.42; 95% CI: −0.62 to −0.21; GRADE: high certainty), with mild gastrointestinal adverse events occurring at nearly twice the rate of controls (RR: 1.97; 95% CI: 1.06–3.67).

Comparative studies of intra-articular biologics have further refined the therapeutic landscape. A 2026 meta-analysis of 18 articles involving 1,326 patients demonstrated that platelet-rich plasma (PRP) outperformed hyaluronic acid (HA) across multiple endpoints, including WOMAC scores at 6 months (SMD = −8.32; p < 0.0001) and 12 months (SMD = −3.15; p < 0.0001), VAS pain at 3 and 6 months, and IKDC functional scores at 6 months, with no significant between-group difference in adverse event rates (OR = 1.31; p = 0.21). A complementary 2025 PRISMA-compliant meta-analysis comparing autologous conditioned serum (ACS) to PRP showed greater long-term pain relief with ACS, with significantly better VAS improvements at three months (p < 0.001), six months (p = 0.03), and 24 months (p < 0.001), alongside sustained WOMAC functional recovery at three and six months (both p < 0.001). A 2026 systematic review comparing genicular nerve radiofrequency ablation (GNRFA) to intra-articular steroid injection (IASI) across four RCTs (n = 379) found that while IASI delivered superior early pain relief and stiffness reduction at one week to three months, GNRFA demonstrated progressively larger effect sizes from one month (SMD: −0.398) to six months (SMD: −1.504), with 22% of GNRFA patients achieving complete pain relief at six months versus 4% in the IASI group; both modalities showed minimal adverse effects.

Surgical and exercise-based interventions also featured prominently in recent evidence. A 2025 quasi-experimental study of 40 patients (mean age 65.20 ± 3.46 years) undergoing total knee arthroplasty (TKA) reported significant reductions in VAS pain scores from 8.40 preoperatively to 3.05 at six months (p < 0.001) and marked improvement in Knee Society Score (KSS) from 36.13 to 75.75 over the same period (p < 0.001), with benefits accumulating at both the three- and six-month assessment points. In the domain of physical rehabilitation, a 2025 quasi-experimental study (n = 32) evaluating supervised versus home-based exercise programs following two PRP injections found that both groups achieved significant improvements in pain, range of motion, and KOOS functional status (p < 0.05), though the supervised cohort demonstrated superior pain reduction and knee flexion ROM outcomes; no significant between-group difference was observed for knee extension ROM (p = 0.378). Safety data were not formally reported across several of these exercise and surgical studies, representing a limitation in comparative risk assessment.

Nexsphere-F's Favorable Safety Profile and Market Potential

In a 2026 exploratory proof-of-concept study conducted in a porcine kidney model, Nexsphere-F (spherical gelatin microparticles) demonstrated a favorable safety and tolerability profile in the context of temporary renal artery embolization. The study enrolled 10 pigs with 20 treated kidneys (10 per group), comparing Nexsphere-F against KIPZA (irregular microparticles). Approximately 5–10 mL of microparticle suspension was injected per kidney, with a mean embolization time of 30 ± 5 minutes. Angiographic evaluations were conducted at immediate, 2-hour, 1-day, and 7-day post-embolization timepoints, with histopathologic assessment performed on 5 kidneys per group.

From a safety standpoint, Nexsphere-F demonstrated complete angiographic recanalization in all 10 treated kidneys at 2 hours post-embolization, with full recanalization confirmed across all kidneys by day 7. Histopathologic evaluation revealed no residual emboli or parenchymal infarction in the Nexsphere-F group — a notably cleaner tissue response compared to the KIPZA group, which exhibited minimal microparticle residue, focal infarction (mean infarcted area of 2.78% ± 1.33%), and endothelial proliferation in arcuate and interlobular arteries. No specific adverse events were reported for Nexsphere-F in this pilot investigation, and the overall tissue injury profile was characterized as minimal.

These preliminary findings position Nexsphere-F as a candidate agent for temporary embolization in clinical scenarios where parenchymal preservation is a primary objective. However, the authors acknowledged the inherent limitations of this exploratory pilot design, emphasizing that larger, adequately powered studies incorporating disease-relevant models and extended follow-up durations will be necessary to substantiate these early observations and support broader clinical translation.

Resorbable Embolization: A Game Changer for Knee OA Pain

The recent European study results for NextBiomedical's Nexsphere-F mark a pivotal moment in the evolving landscape of knee osteoarthritis (KOA) treatment. For patients suffering from chronic KOA pain who have not found relief with conventional therapies, the prospect of a minimally invasive, highly effective option is significant. The study demonstrated a substantial mean 57% reduction in pain and high rates of clinically meaningful improvement, underscoring the potential of genicular artery embolization (GAE) as a viable therapeutic strategy.

What sets Nexsphere-F apart is its use of gelatin-based, fast-resorbable microspheres. Existing evidence indicates that GAE using various embolic particles, including resorbable microspheres, is generally safe and effective for KOA-related pain. However, the resorbable nature of Nexsphere-F's agent could offer a distinct advantage, potentially mitigating concerns associated with permanent embolization and aligning with a preference for temporary interventions where possible. This characteristic positions NextBiomedical to carve out a strong niche in the interventional pain management market.

Strategically, NextBiomedical is well-placed to establish Nexsphere-F as a leading option for KOA non-responders, leveraging this robust European data. The company's pursuit of US market entry through the RESORB trial highlights an ambition to become a global leader in this space. However, it is important to consider that the European study was observational, which, while informative, may carry inherent biases compared to randomized controlled trials. Additionally, while the safety profile was favorable, the reported transient skin discoloration, though minor, is a factor for patient counseling. As GAE continues to gain traction, further long-term data specific to Nexsphere-F will be crucial to solidify its position and demonstrate sustained efficacy beyond current follow-up periods, ensuring it becomes a truly enduring standard of care.